Technical Analysis for XLO - Xilio Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Boomer Buy Setup | Bullish Swing Setup | 0.00% | |
| Calm After Storm | Range Contraction | 0.00% | |
| Upper Bollinger Band Walk | Strength | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Above Upper BB | Strength | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% | |
| Jack-in-the-Box Bullish | Bullish Swing Setup | 3.94% | |
| Parabolic Rise | Strength | 3.94% | |
| Upper Bollinger Band Walk | Strength | 3.94% |
| Alert | Time |
|---|---|
| 1.5x Volume Pace | about 23 hours ago |
| Down 3% | about 23 hours ago |
| Up 3% | about 23 hours ago |
| Down 2 % | about 23 hours ago |
| Down 1% | about 23 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 06/13/2024
Xilio Therapeutics, Inc., a biotechnology company, designs immunotherapies to improve the immune system for cancer patients. Its checkpoint inhibitor programs include XTX101, is a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1 clinical trials in patients with solid tumors; and cytokine programs comprise XTX202, XTX301, and XTX401, which are modified form of IL-2 that is masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Clinical Medicine Solid Tumors Immune System Immunotherapy Tumor Cancer Immunotherapy Immunotherapies Immune Checkpoint Checkpoint Inhibitor Tumor Microenvironment
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Clinical Medicine Solid Tumors Immune System Immunotherapy Tumor Cancer Immunotherapy Immunotherapies Immune Checkpoint Checkpoint Inhibitor Tumor Microenvironment
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 2.593 |
| 52 Week Low | 0.49 |
| Average Volume | 240,640 |
| 200-Day Moving Average | 0.90 |
| 50-Day Moving Average | 0.85 |
| 20-Day Moving Average | 0.92 |
| 10-Day Moving Average | 1.05 |
| Average True Range | 0.12 |
| RSI (14) | 71.83 |
| ADX | 35.89 |
| +DI | 32.75 |
| -DI | 4.91 |
| Chandelier Exit (Long, 3 ATRs) | 1.05 |
| Chandelier Exit (Short, 3 ATRs) | 1.07 |
| Upper Bollinger Bands | 1.29 |
| Lower Bollinger Band | 0.54 |
| Percent B (%b) | 1.04 |
| BandWidth | 81.38 |
| MACD Line | 0.11 |
| MACD Signal Line | 0.06 |
| MACD Histogram | 0.0552 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.51 | ||||
| Resistance 3 (R3) | 1.49 | 1.41 | 1.48 | ||
| Resistance 2 (R2) | 1.41 | 1.37 | 1.42 | 1.47 | |
| Resistance 1 (R1) | 1.37 | 1.34 | 1.39 | 1.38 | 1.46 |
| Pivot Point | 1.29 | 1.29 | 1.30 | 1.30 | 1.29 |
| Support 1 (S1) | 1.24 | 1.24 | 1.27 | 1.26 | 1.18 |
| Support 2 (S2) | 1.16 | 1.21 | 1.17 | 1.17 | |
| Support 3 (S3) | 1.12 | 1.16 | 1.16 | ||
| Support 4 (S4) | 1.13 |
